SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and ...

At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced new customer ...

SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics ...

"Unlocking the human genome has changed the face of cancer care and opened up demand for the next wave of biological insights," said Jacob Thaysen, chief executive officer at Illumina. "Researchers ...

SAN DIEGO, Feb. 26, 2026 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) announced new customer breakthroughs in oncology powered by Illumina’s spatial transcriptomics, 5-base sequencing, and proteomics ...

TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in detecting rare genetic diseases 40% increase in output ...

Illumina's launch of TruPath™ Genome sets a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and ...